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O B J E C T I V E S The study evaluated serial quantitative and qualitative changes in vascular responses
to drug-eluting stents (DES) using optical coherence tomography (OCT).
B A C KG ROUND Serial changes in stent strut coverage and neointima characteristics in DES-treated
lesions have not been sufﬁciently investigated using OCT.
METHOD S Serial OCT was performed in 72 patients with 76 DES-treated lesions at 9 months and
2 years after DES implantation (sirolimus-eluting stent, n  23; paclitaxel-eluting stent, n  20;
zotarolimus-eluting stent, n  25; everolimus-eluting stent, n  8). Serial changes in quantitative
parameters (neointimal thickness, stent strut coverage, and apposition at each strut) and qualitative
characteristics of the neointima were evaluated.
R E S U L T S Mean neointimal thickness signiﬁcantly increased from 164 m to 214 m between 9
months and 2 years (p  0.001), and the percentage of uncovered stent struts signiﬁcantly decreased
(from 4.4% to 2.3%, p  0.001). Completely covered lesions were more frequently observed at 2 years
(44.7% vs. 59.2%, p 0.07). However, the percentage of malapposed struts (0.6% vs. 0.9%, p 0.24) and
incidence of intracoronary thrombi (10.5% vs. 9.2%, p  0.99) were similar. On qualitative evaluation of
neointimal morphology, lipid-laden neointima (27.6% vs. 14.5%, p  0.009) and thin-cap neoatheroma
(13.2% vs. 3.9%, p  0.07) were more frequently detected at 2-year follow-up compared with 9 months.
In matched cross-sectional evaluation, the change of neointimal morphology from homogeneous to
heterogeneous or lipid-laden pattern was observed in 23 (30.3%) of 76 lesions. There was a signiﬁcant
increase in percent neointimal hyperplasia cross-sectional area in those lesions.
CONC L U S I O N S This OCT study suggested that neointimal coverage improved from 9 months to
2 years without signiﬁcant changes in the incidence of malapposed struts and intracoronary thrombus.
Additionally, in-stent neoatherosclerosis including transformation to lipid-laden neointima might
progress during extended follow-up periods after DES implantation. (J Am Coll Cardiol Img 2012;5:
1147–55) © 2012 by the American College of Cardiology Foundation
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1148rug-eluting stents (DES) remarkably sup-
press neointimal growth and improve an-
giographic outcomes compared with bare-
metal stents (1,2). However, late stent
thrombosis has become a critical long-term safety
issue because it can cause serious clinical events,
such as sudden death or acute myocardial infarc-
tion (3,4). Although multifactorial predictors may
be associated with late stent thrombosis, delayed
vascular healing after DES implantation is suggested
as a strong predictor among several factors (3,5). In
addition, recent studies demonstrated that develop-
ment of neoatherosclerosis within neointimal tissues
could be another cause of stent thrombosis due to
neointimal rupture (6,7).
Optical coherence tomography (OCT) is a high-
resolution intravascular imaging modality to evalu-
ate neointimal tissue adequately in vivo. In a pre-
vious OCT study with bare-metal stent–treated
lesions, significant differences in neoath-
erosclerosis were detected within neointi-
mal tissue between 6 months and 5
years after bare-metal stent implantation
(8). However, there have been little
quantitative or qualitative in vivo data
investigating serial changes in neointi-
mal tissue characteristics of DES-
treated lesions using OCT. Therefore,
the present study evaluated serial
changes in quantitative and qualitative
characteristics of neointimal tissue in
DES-treated lesions between 9-month
and 2-year follow-up.
M E T H O D S
Study patients and design. We identified 250 pa-
ients from the OCT registry database of our
nstitute who underwent follow-up OCT examina-
ion at 9 months (3 months) after DES implan-
ation between November 2007 and August 2009.
mong these patients, a second follow-up OCT
xamination at 2 years (3 months) after stent
mplantation was performed in 72 patients. A total
f 76 stented lesions were evaluated serially: 23
irolimus-eluting stents (SES) (Cypher, Cordis,
iami, Florida), 20 paclitaxel-eluting stents (PES)
Taxus, Boston Scientific, Natick, Massachusetts),
5 zotarolimus-eluting stents (ZES) (Endeavor
print, Medtronic, Santa Rosa, California), and 8
verolimus-eluting stents (EES) (Xience, Abbott
ascular, Santa Clara, California). The reasons for
nt(s)
ia
nt(s)
t(s)
ma
nt(s)-year follow-up angiogram were: 1) evidence ofyocardial ischemia by stress test or clinical pre-
entation of coronary artery disease (n  24 le-
ions); or 2) planned follow-up angiography for
ther stented segments (n  52 lesions). The
election of DES at the time of coronary interven-
ion was at the physician’s discretion. Inclusion and
xclusion criteria of follow-up OCT procedures
ave been previously reported (9). Specifically, the
atients with in-stent restenotic lesions treated by
epeated target lesion revascularization before
-year follow-up were excluded from this study.
he study protocol was approved by the institu-
ional review board of our institutes, and written
nformed consent was obtained from all patients
efore the procedure. DES implantation was per-
ormed using conventional techniques and most
atients received dual (aspirin and clopidogrel)
ntiplatelet therapy for at least 12 months. Quan-
itative coronary angiography analysis was previ-
usly described (9). Angiographic late loss was
efined as the difference between follow-up and
ost-procedure minimal lumen diameter.
OCT image protocol and analysis. OCT examination
using a conventional OCT system (Model M2
Cardiology Imaging System, LightLab Imaging,
Westford, Massachusetts) with a motorized pull-
back system at 1.0 mm/s was previously described
(10). OCT analysis was performed by an indepen-
dent investigator blinded to patient and procedural
information. For serial comparison, total stent
length was measured at the 9-month and 2-year
follow-up, and unchanged stent length was con-
firmed in all lesions. Cross-sectional OCT images
at 9 months and 2 years were meticulously matched
using distance from the stent edge and landmarks
such as side branches and calcified plaques. Inade-
quate images including noncircumferential cross
sections, poor quality or mismatched images, and
cross sections with major side branches (diameter
2.0 mm) were excluded from this analysis. A total
of 1,947 matched cross-sectional images at both 9
months and 2 years had analyzable image quality.
Cross-sectional OCT images were analyzed at
1-mm intervals (every 15 frames). Stent and lumi-
nal cross-sectional areas (CSA) were measured at
1-mm intervals, and neointimal hyperplasia (NIH)
CSA was calculated as the stent CSA minus the
luminal CSA. Percent NIH CSA was calculated as
NIH CSA  100/stent CSA. Mean values are
reported in this study. The thickness of NIH was
measured as the distance between the endoluminal
surface of the neointima and the strut (11). AnA B B R E V I A T I O N S
A N D A C R O N YM S
CSA cross-sectional area
DES drug-eluting stent(s)
ES everolimus-eluting ste
IH neointimal hyperplas
CT optical coherence
omography
ES paclitaxel-eluting ste
ES sirolimus-eluting sten
CNA thin-cap neoatherouncovered strut was defined as having an NIH
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1149thickness of 0 m (11). A completely covered lesion
as defined as a stented lesion with 99% of struts
overed with neointima. A malapposed strut was
efined as a strut that had detached from the vessel
all (SES 160 m, PES 130 m, ZES 110
m, EES 100 m) (10–13). The percentage of
malapposed or uncovered struts in each stented
lesion were calculated as the (number of malap-
posed or uncovered struts/total number of struts in
all cross sections of the lesion)  100, respectively.
Qualitative evaluation was performed in stent level
and in matched cross section level at 1-mm intervals
between 9 months and 2 years. Neointimal tissue
was classified as follows (Fig. 1): 1) homogeneous
neointima, a uniform signal rich band without focal
variation or attenuation; 2) heterogeneous neoin-
tima, focally changing optical properties and var-
ious backscattering patterns; and 3) lipid-laden
neointima, a diffuse border, signal-poor region
with marked attenuation (8,14). A thin-cap neo-
atheroma (TCNA) was defined as fibrous cap
thickness at the thinnest part 65 m and an
ngle of lipid-laden neointima 180° (15). The
morphology of thrombi was signal-rich, low-
backscattering protrusions or high-backscattering
Figure 1. Representative Optical Coherence Tomographic Image
Images shown are (A) homogeneous neointima, (B) heterogeneous
tima (arrowheads), (D) intracoronary thrombi (arrow), and (E) neovprotrusions inside the lumen of the artery withsignal-free shadowing on OCT images (dimension
250 m) (9). Visible microvessels were defined as
ell-delineated low backscattering structures 200
m in diameter and showing a trajectory within the
vessel (Fig. 1) (14). The extrastent lumen was defined
when external lumen of the stent was shown in a cross
section (16).
Statistical analysis. Statistical analysis was per-
ormed using SAS software, version 9.1.3 (SAS
nstitute, Cary, North Carolina). Data are ex-
ressed as mean  SD or n (%). Comparisons were
ade using McNemar test for the categorical data,
nd paired t test for the continuous variables.
omparisons between 52 lesions without ischemia
f Neointimal Tissue
intima, (C) thin-cap neoatheroma (arrows) and lipid-laden neoin-
larization (arrows).
Table 1. Baseline Clinical Characteristics (N  72)
Age, yrs 60.4 8.8
Male 51 (70.8)
Acute coronary syndrome 45 (62.5)
Hypertension 37 (51.4)
Diabetes mellitus 23 (31.9)
Dyslipidemia 31 (43.1)
Current smoking 18 (25.0)
Previous myocardial infarction 3 (4.2)s o
neoValues are mean  SD or n (%).
t
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1150and 24 lesions with ischemia at 2-year follow-up
OCT examination were made using Student t test,
chi-square square statistics, or Fisher exact test. If
the distributions were skewed, a nonparametric test
was used. A p value 0.05 was considered statisti-
cally significant.
giographic and Optical Coherence Tomographic Findings
l (n  76) 9 Months 2 Years p Value
angiography
ending artery 34 (44.7) —
ery 17 (22.4) —
ery 25 (32.9) —
55 (72.4) —
3.0 0.3 —
26.5 6.5 —
essure, atm 16.0 2.2 —
—
iameter, mm 2.7 0.4 —
ameter, mm 0.7 0.5 —
iameter, mm 2.8 0.4 —
ameter, mm 2.7 0.3 —
iameter, mm 2.7 0.4 2.8 0.3 0.23
ameter, mm 2.3 0.4 2.0 0.4 0.001
0.39 0.38 0.66 0.43 0.001
, days 276 56 735 79
el analysis
, mm2 7.0 1.6 7.0 1.6 0.92
A, mm2 5.7 1.4 5.4 1.6 0.01
mm2 1.3 0.9 1.7 1.1 0.001
A, % 18.7 11.3 23.4 14.5 0.001
ith any uncovered strut, % 21.2 22.1 12.2 16.9 0.001
ith uncovered strut ratio 7.7 14.5 4.3 11.9 0.001
ith any malapposed strut, % 2.4 5.7 3.1 9.0 0.36
s
ness, m 164 95 214 132 0.001
ncovered struts, % 4.4 6.1 2.3 4.0 0.001
alapposed strut, % 0.6 1.9 0.9 3.5 0.24
ncovered and malapposed 0.3 1.3 0.3 1.9 0.89
is
mbus 8 (10.5) 7 (9.2) 0.99
tima 11 (14.5) 21 (27.6) 0.009
roma 3 (3.9) 10 (13.2) 0.07
ttern 49 (64.5) 47 (61.8) 0.99
34 (44.7) 56 (73.7) 0.001
15 (19.7) 21 (27.6) 0.04
 SD.
a; NIH  neointimal hyperplasia; OCT  optical coherence tomography.R E S U L T S
Baseline characteristics. Baseline characteristics of
he study population are presented in Table 1. The
ime intervals from stent implantation to the first
nd second OCT examinations were 276  55 and
33  78 days, respectively. Quantitative angio-
graphic findings are shown in Table 2. A total of 76
stented lesions were serially evaluated by OCT
without any serious complications.
Serial changes of OCT ﬁndings. Table 2 summarizes
he serial OCT data. Representative cases of the
hange in neointimal coverage, malapposition, and
eointimal tissues are shown in Figure 2. Mean
IH thickness and percent NIH CSA increased
rom 164 m and 18.7% at 9 months to 214 m
and 23.4% at 2 years (p  0.001 for both). The
percentage of uncovered struts significantly de-
creased from 4.4% at 9 months to 2.3% at 2 years
(p  0.001). Completely covered lesions were more
frequently observed at 2 years (44.7% vs. 59.2%,
p  0.07), but approximately one-half of the
stented lesions were still not completely covered
during extended follow-up. In addition, malap-
posed struts and intracoronary thrombi were simi-
larly detected during follow-up (0.6% vs. 0.9% and
10.5% vs. 9.2%, respectively). About one-half of
thrombi were detected over the uncovered strut
(62.5% at 9 months and 42.9% at 2 years) and part
of them was observed over the malapposed strut
(12.5% at 9 months and 14.3% at 2 years). Lipid-
laden neointima (14.5% vs. 27.6%, p  0.009) and
TCNA (3.9% vs. 13.2%, p  0.07) were more
frequently detected at 2 years compared with
9-month follow-up. The incidence of neovascular-
ization also significantly increased from 44.7% at 9
months to 73.7% at 2 years (p  0.001).
Matched cross-sectional evaluation. Mean NIH
thickness increased in 74.4% of cross sections,
which was different according to types of DES
(SES, 81.3%; PES, 60.0%; ZES, 73.8%; EES,
88.9%; p  0.001). The serial change of neointimal
tissue pattern is also shown in Figure 3. The change
of neointimal morphology from homogeneous to
heterogeneous or lipid-laden pattern was ob-
served in 23 (30.3%) of 76 lesions. There was a
significant increase in percent NIH CSA in those
lesions (Fig. 4).
OCT ﬁndings according to presence of ischemia at
2-year follow-up. Compared to 52 lesions with-
out ischemia, the incidence of thrombi was sig-Table 2. Coronary An
Tota
Quantitative coronary
Target vessel
Left anterior desc
Left circumﬂex art
Right coronary art
Type B2 or C lesion
Stent diameter, mm
Stent length, mm
Maximal inﬂation pr
Pre-intervention
Reference vessel d
Minimal lumen di
Post-intervention
Reference vessel d
Minimal lumen di
Follow-up
Reference vessel d
Minimal lumen di
Late loss, mm
OCT
Time interval to OCT
Quantitative analysis
Cross-sectional lev
Mean stent CSA
Mean lumen CS
Mean NIH area,
Percent NIH CS
Cross sections w
Cross sections w
0.3, %
Cross sections w
Strut level analysi
Mean NIH thick
Percentage of u
Percentage of m
Percentage of u
struts, %
Qualitative analys
Intracoronary thro
Lipid-laden neoin
Thin-cap neoathe
Heterogeneous pa
Neovascularization
Extrastent lumen
Values are n (%) or meannificantly higher in 24 lesions with ischemia in
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11512-year follow-up OCT examination (Fig. 5A).
The serial changes of neointimal tissue pat-
tern between the 2 groups are also shown in
Figure 5B.
D I S C U S S I O N
This serial OCT study showed changes in both
quantitative and qualitative characteristics of the
neointima between 9 months and 2 years after DES
Figure 2. Representative Cases of Changes in Neointimal Cover
(A) Uncovered struts at 9 months were covered with neointima on fol
ture appeared over uncovered struts during serial follow-up (white arr
follow-up (yellow arrows). (D) Increase in the low-density signal within
arrows) and 2 years (yellow arrows).
(%
)
0
20
40
60
80
100
9 Mo
Overall
88.6% 84.9%
Sirolimus
88.0% 80.8%
Paclitaxel
83.6% 79.0%
2 Yr 9 Mo 9 Mo2 Yr 2 Yr
10.2% 12.5% 11.8% 17.5%
13.8% 16.3%
1.2% 2.6% 0.2% 1.7% 2.6% 4.7%
Figure 3. Serial Change of Neointimal Tissue PatternThe serial change of neointimal tissue pattern was different in each druimplantation. There were significant increases in
mean NIH thickness, percent NIH CSA, percent-
age of uncovered struts, lipid-laden neointima, and
TCNA, but similar incidences of malapposed struts
and intracoronary thrombi.
A higher incidence of late stent thrombosis has
been reported in patients following DES implanta-
tion compared to bare-metal stents (3,17). Ade-
quate vascular healing including sufficient endothe-
, Malapposition, and Neointimal Tissues
up at 2 years (white arrows). (B) A low-density abnormal tissue struc-
). (C) Extrastent lumen not present at 9 months was noted at 2-year
terogeneous neointima was observed between 9 months (white
otarolimus
4.0% 94.1%
Everolimus
Lipid-Laden Neointima
Heterogeneous Pattern
Homogeneous Pattern
88.3% 89.6%
 Mo 9 Mo2 Yr 2 Yr
4.7% 4.3%
11.7% 8.4%
1.3% 1.6% 0% 2.0%age
low-
ows
heZ
9
9g-eluting stent by matched cross-sectional evaluation.
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1152lial coverage after stent implantation could play a
protective role against late stent thrombosis and
might be an important parameter in determining
the optimal duration of dual antiplatelet therapy
(5,18). However, detection of thin-layer neointimal
tissue in vivo has been a challenging problem.
Recently, high-resolution intravascular OCT was
introduced in clinical practice and can evaluate the
vascular healing pattern including stent strut coverage
and proper apposition. Previous OCT studies re-
ported that the percentage of uncovered struts was
15% at 3 months (19), 8.9% to 13.3% at 6 months
(20–22), and 12.2% at 9 to 12 months after SES
implantation (23). These figures were 2.7% to 7.1%
at 6 months (21,22) and 4.9% at 9 to 12 months
after PES implantation (24); and 0.01% at 3
months (10), 0.02% at 6 months (21), and 0.01% at
9 to 12 months after ZES implantation (23). As the
time interval from stent implantation to follow-up
OCT was longer, there was a trend toward de-
creased rate of uncovered struts in general. How-
ever, because the previous OCT studies were not
performed serially, the findings of decreased ten-
dency in the rate of uncovered struts with time
could not be adequately validated. In addition, until
now, serial or long-term (2 years) follow-up OCT
studies after DES implantation were very rare and
(%
)
0
5
10
15
20
25
30
Percent Neointimal
Hyperplasia
Cross-Sectional Area
Pro
Unco
9 Mo 9 M2 Yr
Figure 4. Relationship Between Quantitative Parameters and Se
The change of neointimal morphology from homogeneous to hete
There was a signiﬁcant increase in percent neointimal hyperplasia c
2 years.the number of study patients in those studies wassmaller (16,25). One serial OCT study with 21
SES-treated lesions reported that the percentage of
uncovered struts decreased from 3.2% at 2-year
follow-up to 0.9% at 4 years (16). Another 2-year
follow-up OCT study showed that the percentage
of uncovered struts was 6.5% in 20 SES-treated
lesions and 3.7% in 12 PES-treated lesions (25). In
this serial OCT study with 76 DES-treated lesions,
improvement of neointimal coverage was directly
observed: mean neointimal thickness, 164 m to
214 m (p  0.001); percentage of uncovered stent
struts, 4.4% to 2.3% (p  0.001).
Despite augmentation of endothelial coverage in
this study, there was no significant change in the
incidence of malapposition and intracoronary
thrombi between 9 months and 2 years after DES
implantation. These results were similar to those in
the previous serial OCT study with SES (16). The
previous study reported a significant increase in the
percentage of malapposed struts from 2.2% at 2
years to 3.0% at 4 years (p  0.044) without
significant change in the incidence of intracoronary
thrombi (24% vs. 29%, respectively; p  1.0) (16).
These findings suggest that DES may be still
biologically active and vascular responses of DES-
treated lesions may not have completely stabilized
up to 2 years after stent implantation. The discrep-
tion Of
ed Strut
Presence Of 
Thrombus
9 Mo2 Yr 2 Yr
No change of homogeneous pattern (N = 16)
Homogeneous to heterogeneous
or lipid-laden pattern (N = 23)
No change of heterogeneous
or lipid-laden pattern (N = 37)
Change of Neointimal Tissue Morphology
neous or lipid-laden pattern was observed in 30.3% of 76 lesions.
-sectional area in those lesions. *p  0.05 between 9 months andpor
ver
o
rial
roge
rossancy between improvement of neointimal cover-
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1153age and lack of decrease (or increase) in the
incidence of malapposed struts or intracoronary
thrombi might be partly explained by pathologi-
cal findings in previous autopsy studies: fibrin
accumulation persists around the struts lacking
endothelium and the mean percent endotheliali-
zation of DES is no more than 60%, regardless of
implant duration (5,16,26). Therefore, there is
the possibility that OCT might overestimate the
extent of neointimal coverage over the stent strut
because OCT cannot differentiate fibrin around
struts from healthy neointima.
Although incomplete endothelialization and
strut coverage after DES implantation could be a
critical cause of late stent thrombosis, a recent
autopsy study suggested that neoatherosclerosis
might be another possible cause (6). A previous
OCT study with bare-metal stent–treated lesions
showed that the incidence of lipid-laden neointima
and neovascularization within neointimal tissue was
significantly higher during the late phase (5 years
after stent implantation) compared to early phase
Percent Neointimal
Hyperplasia
Cross-Sectional Area
Proportion of
Uncovered Strut
Presence
Thromb
(%
)
9 Mo 9 Mo 9 Mo2 Yr 2 Yr 2 
A
0
5
10
15
20
25
30
Group 1 (Lesions with ischemia, N = 24)
Group 2 (Lesions without ischemia, N = 52)
Figure 5. Comparison Between Lesions With Versus Without Isc
Quantitative (A) and qualitative (B) comparison of neointimal tissue
ischemia at 2-year follow-up angiography are shown. *p  0.05 be
emia and those without ischemia.(6 months after stent implantation) (8). Neoath-erosclerosis tends to develop earlier in DES-treated
lesions compared with bare-metal stent–treated le-
sions. Although atherosclerotic changes do not
appear until 2 years after bare-metal stent implan-
tation and remain a rare finding at 4 years, athero-
sclerotic changes, including foamy macrophage in-
filtration and early necrotic core formation, were
observed in 40% of patients 9 months after SES
implantation (27). A more recent autopsy study also
reported that the incidence of neointimal athero-
sclerotic change was significantly greater in DES-
treated lesions (31%) compared to bare-metal
stent–treated lesions (16%) (6). Compared with
DES 20 months after implantation, DES 20
months after implantation had a higher incidence of
TCNA (69% vs. 33%, p  0.012) in a recent OCT
study (28). The incidence of neoatherosclerosis in
this autopsy study is similar to the presence of
lipid-laden neointima (27.6%) in the current study
at 2 years follow-up OCT examination. A discrep-
ancy in the incidence of neoatherosclerosis between
OCT and histology examination might result from
Group 1
(lesions with
ischemia, N = 24)
(%
)
9 Mo 2 Yr9 Mo
29.2%
58.3%
12.5%
29.2%
33.3%
37.5%
2 Yr
B
0
20
40
60
80
100
Group 2
(lesions without
ischemia, N = 52)
40.4%
46.2%
13.4%
38.5%
38.5%
23.0%
Lipid-Laden Neointima
Heterogeneous Pattern
Homogeneous Pattern
ia at 2-Year Follow-Up
racteristics between lesions with ischemia and those without
n 9 months and 2 years. †p  0.05 between lesions with isch- of
us
Yr
hem
cha
tweedifferent follow-up duration following stent im-
n
T
t
L
t
o
9
H
H
S
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1154plantation, the various characteristics of study pop-
ulation and the type of DES (6). However, there
have been little data to evaluate the serial changes in
eointimal characteristics in DES-treated lesions.
his is the first OCT study to perform serial evalua-
ion of qualitative characteristics of the neointima.
ipid-laden neointima, TCNA, and neovasculariza-
ion were increased, which is suggestive of progression
f neoatherosclerosis within neointimal tissue between
months and 2 years after DES implantation.
Study limitations. The study population was rela-
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1
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